Related Experiment Videos
Effect of iron therapy on serum ferritin levels in iron-deficiency anemia
Insights
Serum ferritin levels in adults with iron-deficiency anemia do not rise with standard treatment until hemoglobin normalizes. Higher iron doses may cause a temporary ferritin increase, indicating excess iron absorption.
Area of Science:
- Hematology
- Biochemistry
Background:
- Serum ferritin is a key indicator of body iron stores.
- Exceptions to this include liver disease, malignant conditions, and iron deficiency anemia treatment.
Purpose of the Study:
- To evaluate the impact of standard and double oral ferrous sulfate doses on serum ferritin levels in adults with iron-deficiency anemia.
- To compare the timing of serum ferritin rise with hematologic response during treatment.
Main Methods:
- 14 adult patients with iron-deficiency anemia were studied.
- Serum ferritin levels were measured using radioimmunoassay before and after treatment with standard (300 mg t.i.d.) or double (600 mg t.i.d.) oral ferrous sulfate doses.
Main Results:
- Standard dose treatment did not elevate serum ferritin within the first 3 weeks, despite hematologic improvement.
- Double dose treatment resulted in a serum ferritin rise within 2 days in 7 out of 9 patients.
- Serum ferritin levels returned to subnormal within 6 days of discontinuing iron in the double-dose group.
Conclusions:
- Standard iron deficiency anemia treatment in adults does not increase serum ferritin until hemoglobin levels normalize.
- The early rise in serum ferritin with higher iron doses suggests iron absorption exceeding erythropoiesis needs, leading to temporary storage.
- Rapid depletion of these stores is reflected by a prompt decrease in serum ferritin upon iron discontinuation.
Abstract:
The level of serum ferritin is a reliable indicator of body iron stores. Exceptions include liver disease, malignant diseases, and treatment of iron-deficiency anemia. The latter was noted in iron-deficient infants who showed a rise of serum ferritin to normal levels in the first week of treatment. To evaluate this in adults, 14 patients with iron-deficiency anemia were studied prior to and after beginning treatment with oral ferrous sulfate in standard dose, 300 mg t.i.d., or double dose, 600 mg t.i.d. Serum ferritin was assayed by radioimmunoassay. No rise occurred in the first 3 wk in 5 patients treated with standard dose, although hematologic response occurred. With double dose, 7 of 9 showed a ferritin rise in 2 days with return to subnormal levels within 6 days of discontinuing iron. This study indicates that standard treatment of iron deficiency anemia in adults does not cause a rise in serum ferritin until hemoglobin levels are normal. The early rise seen with double dose is most likely due to absorption of iron in excess of utilization for erythropoiesis resulting in temporary storage. When iron is discontinued, stores are rapidly depleted as reflected by the prompt decrease in serum ferritin.